Review Article

Beneficial Effect of Statin Therapy on Arterial Stiffness

Mona Alidadi,1 Fabrizio Montecucco2,3 Tannaz Jamialahmadi,1,4 Khalid Al-Rasadi,5 Thomas P. Johnston,6 and Amirhossein Sahebkar6,7,8,9

1Department of Nutrition, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
2IRCCS Ospedale Policlinico San Martino Genoa-Italian Cardiovascular Network, 10 Largo Benzi, 16132 Genoa, Italy
3First Clinic of Internal Medicine, Department of Internal Medicine, University of Genoa, 6 viale Benedetto XV, 16132 Genoa, Italy
4Department of Food Science and Technology, Quchan Branch, Islamic Azad University, Quchan, Iran
5Medical Research Centre, Sultan Qaboos University, Muscat, Oman
6Division of Pharmacology and Pharmaceutical Sciences, School of Pharmacy, University of Missouri-Kansas City, Kansas City, MO 64108, USA
7Biotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran
8Applied Biomedical Research Center, Mashhad University of Medical Sciences, Mashhad, Iran
9School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran

Correspondence should be addressed to Amirhossein Sahebkar; amir_saheb2000@yahoo.com

Received 19 January 2021; Revised 1 March 2021; Accepted 17 March 2021; Published 31 March 2021

Academic Editor: Marco Guglielmo

Copyright © 2021 Mona Alidadi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Arterial stiffness describes the increased rigidity of the arterial wall that occurs as a consequence of biological aging and several diseases. Numerous studies have demonstrated that parameters to assess arterial stiffness, especially pulse-wave velocity, are predictive of those individuals that will suffer cardiovascular morbidity and mortality. Statin therapy may be a pharmacological strategy to improve arterial elasticity. It has been shown that the positive benefits of statin therapy on cardiovascular disease is attributable not only to their lipid-lowering capacity but also to various pleiotropic effects, such as their anti-inflammatory, antiproliferative, antioxidant, and antithrombotic properties. Additionally, statins reduce endothelial dysfunction, improve vascular and myocardial remodeling, and stabilize atherosclerotic plaque. The aim of the present review was to summarize the evidence from human studies showing the effects of statins on arterial stiffness.

1. Introduction

Arterial stiffness, as an indicator of structural and functional changes in the arterial wall, occurs as a result of the aging process and the consequence of several diseases such as metabolic syndrome, hypertension, hypercholesterolemia, and chronic inflammatory disease [1–3]. Arterial stiffness is defined as the decreased ability of an arterial wall to dilate and contract in response to an alteration in intraluminal pressure [4]. This phenomenon is thought to have multifactorial pathophysiology, including disturbances in hormone levels, inflammatory responses, oxidative balance, decreased nitric oxide (NO) bioavailability, and increased shear stress induced by risk factors such as hyperlipidemia and hypertension [5–7].

Arterial stiffening is accompanied by several important processes, including the breakage and reduction of elastin fibers, increases in collagen deposition, transforming growth factor-β (TGF-β), intercellular adhesion molecules (ICAM), and proinflammatory cytokines. Additionally, arterial stiffness is also accompanied by the accumulation of advanced glycation end-products (AGEs), activation of matrix metalloproteinases (particularly MMP-2), and infiltration of smooth muscle cells, macrophages, and mononuclear cells [1, 3, 8, 9]. This remodeling and reduction of elastic properties ( stiffening ) at the level of elastic arteries is called arteriosclerosis [10]. Though there are many parameters for evaluation of vascular stiffness, the most common are pulse-wave velocity (PWV), augmentation index (AIx), augmentation pressure (AP), cardio-ankle vascular index (CAVI), arterial
compliance, transit time of the reflected wave (Tr), stiffness index (SI), and reflection index (RI) [11–16]. Among the various parameters, carotid-femoral PWV (cf-PWV), which is the most precise method to use, because of its relative ease in evaluation, relatively inexpensive cost, reliability, safety, noninvasiveness, and, most importantly, because of the strong body of evidence confirming its association with increased risk for an initial cardiovascular event [17–19]. It has been demonstrated that elevated PWV is a strong predictor of cardiovascular incidence and mortality, independent of traditional risk factors [20–25].

Treatment strategies to improve arterial elasticity involve pharmacological and nonpharmacological methods (such as weight loss, restriction in salt intake, smoking cessation, and increasing aerobic physical activity). Though pharmacological interventions are mainly based on antihypertensive drugs, numerous studies have revealed the protective effects of statins, also known as HMG-CoA reductase inhibitors, against vascular stiffening [1, 26]. Several investigations have demonstrated a strong association between lipid levels (high TG, high LDL-cholesterol, non-HDL-cholesterol, high TG/HDL-C, TC/HDL-C ratio, etc.) and arterial stiffness. Kim et al. reported a modest increase in arterial stiffness due to dyslipidemia only in women [27]. In another study, Mozos et al. revealed that increased LDL-cholesterol levels correlated with central systolic and diastolic blood pressure, PWV, and pulse pressure amplification [28]. Moreover, it was shown that non-HDL-cholesterol, TG, and the TC/HDL-cholesterol ratio were consistently associated with arterial stiffness independent of LDL-cholesterol in a Chinese population [29]. In addition to the LDL-lowering effect of statins, given their pleiotropic effects such as anti-inflammatory and antioxidant capabilities, this class of lipid-modifying agents may play a beneficial role in arterial stiffness [5, 7, 30–34].

This paper is aimed at summarizing evidence from human studies (Table 1) describing the effects of statins on arterial stiffness and providing an overview of proposed mechanisms that are thought to mediate this effect.

2. Simvastatin

The effect of simvastatin on arterial elasticity has been assessed in a number of clinical trials. In a randomized, double-blind, placebo-controlled study, the protective effect of simvastatin against arterial stiffness induced by inflammation (by typhoid vaccine) was evaluated in 50 healthy volunteers. In this study, aortic PWV, as well as flow-mediated dilatation (FMD), was assessed three times, at baseline, following 14 days of treatment with either simvastatin (40 mg/day) or placebo, and 8 h after a typhoid vaccination on the morning of day 15. The aortic PWV of the placebo group was significantly elevated following vaccination (5.80 ± 0.87 (baseline) vs. 6.21 ± 0.97 m/s (after vaccination on day 15), 95% CI 0.19, 0.62, P = 0.002). However, the aortic PWV was significantly reduced in the simvastatin group (5.68 ± 0.73 (baseline) vs. 5.72 ± 0.74 m/s (after vaccination on day 15), 95% CI 0.19, 0.27, P = 0.9). Interestingly, typhoid vaccine did not affect AP, Alx, mean arterial pressure, or brachial PWV in either group [35]. Also, in a 6-week randomized, parallel-group, placebo-controlled study, 64 subjects with confirmed chronic obstructive pulmonary disease (COPD) were enrolled and randomized to ingest either simvastatin (20 mg/day) or placebo. In this trial, patients with high baseline aortic PWV (PWV > 10 m/sec, n = 22) exhibited a statistically significant improvement in aortic PWV in comparison to placebo (-2.8 m/sec, P = 0.03) [36]. In another trial, 51 patients with primary arterial hypertension and high-normal serum cholesterol levels were randomized to receive simvastatin (20 mg/day) or placebo, each for 6 months. A significant improvement was observed in PWV values of the simvastatin-treated group (from 13.21 ± 1.83 m/s initially to 9.18 ± 0.59 m/s, P < 0.01), while this trend was nonsignificant in the placebo group (12.98 ± 1.61 m/s initially vs. 11.84 ± 1.19) [37].

In a different randomized, double-blind, cross-over trial, 100 participants with a history of statin myalgia were assigned to consume daily 20 mg simvastatin, or matched placebo, for 8 weeks. In this study, vascular stiffness indices included central PWV, peripheral PWV, Alx, AP, and central arterial pressure and were evaluated before and after each treatment. At the end of the study, the central PWV significantly improved, compared with baseline, following simvastatin treatment (P = 0.01) [38]. In yet another double-blind, cross-over study, Shige et al. assessed the effects of simvastatin (20 or 40 mg/day) therapy versus placebo on arterial compliance and central and peripheral PWV in 20 hypercholesterolemic subjects. After 4 weeks of simvastatin treatment, peripheral PWV significantly decreased compared to placebo (9.40 ± 1.30 vs. 10.12 ± 1.27, P = 0.028) [39]. An additional cross-over study, which included 20 patients with active rheumatoid arthritis, randomly assigned the patients to receive either 20 mg/day simvastatin or 10 mg ezetimibe, for 6 weeks. Among arterial stiffness parameters (aortic PWV, Alx, and AP), PWV substantially improved following both treatments, even though ezetimibe is technically not classified as a statin drug [40].

In a nonrandomized study, forty hypercholesterolemic men and women were divided into four groups. Group 1 consisted of previously untreated patients who received simvastatin at 40 mg/day; group 2 was comprised of patients previously treated with 40 mg/day simvastatin but received simvastatin at 80 mg/day during the study; group 3 was previously untreated patients who received ezetimibe at 10 mg/day; and group 4 included patients previously treated with 40 mg/day simvastatin, and who continued to receive simvastatin at 40 mg/day, together with 10 mg/day of ezetimibe. After 3 months of treatment, only the patients in group 1 (simvastatin 40 mg/day) showed a significant (P < 0.001) reduction in Alx (30.2 ± 8.3% (baseline; i.e., prior to treatment) to 21.6 ± 6.5% (after 3 months of treatment)) [41]. In a study by Gepner et al. it was reported that simvastatin may have a temporary influence on aortic stiffness. In this trial, 88 middle-aged adults at increased risk for dementia were randomly assigned to receive simvastatin (40 mg/day), or matched placebo, for 18 months. By 12 months, the Alx was significantly reduced when compared to the placebo group (-2.3% change from baseline (statin group) vs. 1.2%
Table 1: List of clinical trials reporting the effects of statin therapy on arterial stiffness parameters.

| Author, year       | Study design                | Interventions                     | Statin dose | Duration | Population | Number of participants | Method of arterial stiffness assessment | Main finding                                                                 |
|--------------------|-----------------------------|-----------------------------------|-------------|----------|------------|------------------------|----------------------------------------|--------------------------------------------------------------------------------|
| Wallace et al., 2010 [35] | Randomized, double-blind, placebo-controlled | 1. Simvastatin 2. Placebo | 40 mg/d | 14 days | Healthy volunteers aged 20–40 years | 50 | Aortic and brachial PWV, AIx, and AP | Compared with placebo, pretreatment with simvastatin significantly suppressed the enhancement of aortic PWV following typhoid vaccination. |
| John et al., 2015 [36]     | Randomized, double-blind, placebo-controlled | 1. Simvastatin 2. Placebo | 20 mg/d | 6 weeks | COPD patients | 64 | Aortic PWV | Compared to placebo, arterial stiffness significantly reduced in patients with a high baseline aortic PWV. |
| Kurpesa et al., 2004 [37]   | Randomized, placebo-controlled | 1. Simvastatin 2. Placebo | 20 mg/d | 6 months | Individuals with primary arterial hypertension and high-normal serum cholesterol level | 52 | PWV | PWV lowered in simvastatin group compared to baseline |
| Ballard et al., 2015 [38]   | Randomized, double-blind, cross-over | 1. Simvastatin 2. Placebo | 20 mg/d | 8 weeks | Patients with a history of statin myalgia | 100 | Central PWV, peripheral PWV, AIx, and AP | Central PWV improved in simvastatin treatment group. |
| Shige et al., 2001 [39]     | Randomized, double-blind cross-over | 1. Simvastatin 2. Placebo | 20 or 40 mg/d | 4 weeks | Hypercholesterolemic patients | 20 | Central and peripheral PWV, arterial compliance | Peripheral PWV significantly improved following simvastatin treatment. |
| Mäki-Petäjä et al., 2007 [40] | Randomized double-blind cross-over | 1. Simvastatin 2. Ezetimibe | 20 mg/d | 6 weeks | Patients with active rheumatoid arthritis | 20 | Aortic PWV, AIx, and AP | There was substantial reduction in PWV following both treatments compared to baseline. |
| Efrati et al., 2007 [41]    | Nonrandomized                | 1. Simvastatin 2. Ezetimibe 3. Ezetimibe + simvastatin (40 mg/d) | 40 mg/d 80 mg/d | 3 months | Hypercholesterolemic patients | 40 | AIx | A marked reduction was observed in the simvastatin 40 mg group. |
| Gepner et al., 2019 [42]    | Randomized, double-blind, placebo-controlled | 1. Simvastatin 2. Placebo | 40 mg/d | 12 months | Middle-aged adults at increased risk for dementia | 88 | AIx | A transient improvement was observed at 12 months. |
| Balaguer et al., 2016 [43]   | Randomized, double-blind, placebo-controlled | 1. Simvastatin 2. Placebo | 40 mg/d | 12 weeks | Stable COPD | 18 | PWV, AIx | No significant changes were observed. |
| Cash et al., 2013 [44]      | Randomized, single-blind, placebo-controlled | 1. Simvastatin 2. Placebo | 20 mg/d | 12 months | Primary biliary cirrhosis patients with hypercholesterolaemia | 13 | Aortic PWV, AIx75, and Tr | No significant changes were observed. |
| Wang et al., 2012 [45]      | Single-arm                   | Atorvastatin                     | 20 mg/d | 6 months | Hypertensive patients | 73 | baPWV | baPWV was reduced significantly compared with baseline. |
| Author, year          | Study design | Interventions | Statin dose | Duration   | Population                                                                 | Number of participants | Method of arterial stiffness assessment                                                                 | Main finding                                                                 |
|-----------------------|--------------|---------------|-------------|------------|-----------------------------------------------------------------------------|------------------------|----------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------|
| Shinohara et al., 2005 [46] | Single-arm   | Atorvastatin  | 10 mg/d     | 6 months   | Type-2 diabetic patients with hypercholesterolemia                          | 22                     | Femoral-anklePWV, heart-carotid PWV, heart-brachial PWV, and heart-femoral PWV                        | A reduction in femoral-ankle PWV was perceived.                              |
| Castejon et al., 2017 [47] | Single-arm   | Atorvastatin  | 20 mg/d     | 8 weeks    | Systemic lupus erythematosus females                                         | 37                     | Aortic PWV                                                                                                | PWV significantly improved in patients with baseline pathological arterial stiffness. |
| Van Doornum et al., 2011 [48] | Single-arm   | Atorvastatin  | 20 mg/d     | 6 weeks    | Patients with rheumatoid arthritis                                          | 29                     | AIx                                                                                                      | AIx was decreased by the treatment.                                           |
| Rateford et al., 2011 [49] | Single-arm   | Atorvastatin  | 80 mg/d     | 14 days    | Stroke-free and statin-naive subjects over age 45                           | 40                     | SI                                                                                                       | SI significantly reduced at day 30.                                           |
| Kontopoulos et al., 2002 [50] | Single-arm   | Atorvastatin  | 20 mg/d     | 2 years    | Hypercholesterolemic patients                                               | 36                     | SI                                                                                                       | Aortic SI was significantly reduced by 14%.                                   |
| Leibovitz et al., 2001 [51] | Single-arm   | Atorvastatin  | Starting dose: 10 mg/d (mean dose: 16 ± 1.6 mg/d) | 20 weeks | Patients with severe hypercholesterolemia                                   | 17                     | Arterial compliance                                                                                       | Small artery compliance was significantly increased with treatment.           |
| Leibovitz et al., 2003 [52] | Single-arm   | Atorvastatin  | 10-20 mg/d  | 3 months   | Hypertensive hyperlipidemic patients                                         | 21                     | Arterial compliance (small and large arteries)                                                          | Small artery compliance significantly elevated by atorvastatin treatment.    |
| Akgullu et al., 2008 [53] | Single-arm   | Atorvastatin  | 40 mg/d     | 6 months   | Patients with coronary artery disease                                        | 33                     | Small and large arteries compliance                                                                     | Arterial compliance significantly improved after treatment.                  |
| Yamaguchi et al., 2010 | Single-arm   | Atorvastatin  | 20 mg/d     | 6 months   | Type-2 diabetic patients with high non-HDL-C levels receiving atorvastatin (10 mg/day) | 39                     | CAVI                                                                                                     | CAVI declined substantially by 4.6%.                                         |
| Tulmaç et al., 2012 [54] | Single-arm   | Atorvastatin  | 80 mg       | Acute      | Dyslipidemic patients without atherosclerosis                               | 30                     | RI, SI                                                                                                   | Arterial stiffness did not improve with the treatment.                       |
| Ozaki et al., 2006 [55] | Single-arm   | Atorvastatin  | 10 mg/d     | 6 months   | Hypercholesterolemic patients                                               | 30                     | baPWV                                                                                                    | PWV was unaffected by the treatment.                                         |
| Grigoropoulou et al., 2019 [56] | Nonrandomized | 1. Atorvastatin (+Mediterranean) | 10 mg/d     | 3 months   | Subjects with type-2 diabetes and dyslipidemia                              | 79                     | Aortic PWV, carotid-radial PWV                                                                          | Aortic PWV significantly improved in simvastatin group compared to diet alone. |
| Author, year          | Study design                      | Interventions                                                                 | Statin dose | Duration | Population                        | Number of participants | Method of arterial stiffness assessment | Main finding                                                                                       |
|-----------------------|-----------------------------------|-------------------------------------------------------------------------------|-------------|----------|-----------------------------------|------------------------|----------------------------------------|-----------------------------------------------------------------------------------------------|
| Meng et al., 2009 [57]| Nonrandomized                     | 1. Atorvastatin (+low-fat diet)  2. Mediterranean diet                        | 10 mg/d     | 12 months | CAD patients with hyperlipidemia  | 63                     | Aortic PWV, carotid-radial PWV, and carotid-distal PWV | Compared with the control group and baseline, PWV substantially decreased after 6 months.   |
| Huang et al., 2014 [58] | Randomized                        | 1. Atorvastatin (in combination with levamlodipine besylate) 2. Levamlodipine besylate treatment | 20 mg/d     | 8 weeks  | Hypertensive patients with dyslipidemia and body’s inflammatory response | 120                    | PWV                                     | Atorvastatin significantly improved PWV compared to the levamlodipine besylate-treated group. |
| Orr et al., 2009 [59]  | Randomized, double-blind, placebo-controlled | 1. Atorvastatin  2. Placebo                                                   | 80 mg/d     | 12 weeks | Overweight and obese middle-aged and older adults | 26                     | Aortic and carotid-radial PWV, SI, and arterial compliance | Aortic PWV, SI, and arterial compliance improved compared to placebo.                        |
| Kanaki et al., 2013 [60] | Randomized, double-blind, placebo-controlled | 1. Atorvastatin  2. Placebo                                                   | 10 mg/d     | 6 months  | Hypertensive and hypercholesterolemic patients | 50                     | Aortic PWV, normalized PWV, AIx75, and AP | Arterial stiffness parameters significantly improved compared to placebo.                      |
| Manisty et al., 2009 [61]  | Randomized, single-blind          | 1. Atorvastatin  2. Placebo                                                   | 10 mg/d     | 12–18 months | Hypertensive patients               | 142                    | Carotid AIx, AP, and RI                  | Carotid AIx, AP, and RI from the body significantly improved compared to placebo.            |
| Davenport et al., 2015 [62] | Randomized, open-label            | Atorvastatin                                                                 | 10 mg/d 80 mg/d | 3 months 12 months | Male patients with type-2 diabetes | 51                     | Aortic PWV                             | PWV decreased at 3 months and 12 months.                                                      |
| Lee and Kim, 2008 [63] | Randomized                        | Atorvastatin                                                                  | 10 mg/d 40 mg/d | One week 8 weeks | Patients with moderate cholesterolia | 51                     | Carotid-radial PWV                      | PWV improved after 8 weeks of 40 mg atorvastatin treatment, and a significant difference was observed between the groups. |
| Tousoulis et al., 2013 [64] | Randomized, double-blind, cross-over | Atorvastatin                                                                  | 10 mg/d 40 mg/d | 4 weeks  | Ischemic heart failure patients    | 22                     | AIx75                                  | Compared with the low-dose group, 40 mg/d atorvastatin treatment significantly improved AIx75. |
| Karter et al., 2003 [65] | Randomized, double-blind          | Atorvastatin                                                                  | 20 mg/d 80 mg/d | 3 months | Hypercholesterolemic patients     | 20                     | Distensibility coefficient              | There was noticeable increased in distensibility coefficient of both groups.                 |
| Mukherjee et al., 2008 [66] | Randomized, placebo-controlled   | 1. Atorvastatin  2. Placebo                                                   | 10 mg/d     | 6 months  | Normotensive normolipidemic persons with type-2 diabetes | 57                     | baPWV                                  | baPWV improved significantly in the atorvastatin group compared with baseline.               |
| Author, year                     | Study design                          | Interventions                      | Statin dose | Duration       | Population                                                        | Number of participants | Method of arterial stiffness assessment | Main finding                                                                 |
|---------------------------------|---------------------------------------|------------------------------------|-------------|----------------|------------------------------------------------------------------|------------------------|------------------------------------------|--------------------------------------------------------------------------------|
| Kabaklić and Fras, 2017 [67]    | Randomized, double-blind, placebo-controlled | 1. Atorvastatin 2. Placebo         | 20 mg/d     | 3 months 6 months | Patients with angina pectoris and normal coronary angiogram       | 58                     | AIX, AIx75                              | No marked change was perceived.                                                   |
| Fassett et al., 2010 [68]       | Randomized, double-blind, placebo-controlled | 1. Atorvastatin 2. Placebo         | 10 mg/d     | 3 years         | Patients with CKD                                                | 37                     | Aortic PWV, AIx, arterial pressure      | No significant changes were observed.                                              |
| Joyeux-Faure et al., 2014 [69]  | Randomized, double-blind, placebo-controlled | 1. Atorvastatin 2. Placebo         | 40 mg/d     | 12 weeks        | Obstructive sleep apnea syndrome patients                         | 51                     | Aortic PWV                              | PWV did not alter compared to the placebo group.                                   |
| Hong et al., 2013 [70]          | Randomized, double-blind, cross-over, placebo-controlled | 1. Atorvastatin 2. Placebo         | 40 mg/d     | 6 weeks         | First-degree relatives of patients with premature coronary artery disease patients with endothelial dysfunction | 35                     | AIX                                      | No marked difference was observed.                                                 |
| Raison et al., 2001 [71]        | Randomized, double-blind, placebo-controlled | 1. Atorvastatin 2. Placebo         | 10 mg/d     | 12 weeks        | Patients with hypertension and hypercholesterolemia              | 23                     | Aortic PWV, carotid AIx                 | No significant difference was perceived between the groups.                       |
| Cohn et al., 2009 [72]          | Randomized, double-blind, placebo-controlled | 1. Atorvastatin 2. Placebo         | 10 mg/d     | 8 weeks         | Patients with concomitant hypertension and dyslipidemia           | 325                    | Small artery compliance, large artery compliance | No significant changes were observed.                                              |
| Mikhin et al., 2016 [73]        | Single-arm                            | Rosuvastatin                       | 10-40 mg/d  | 1.5 years       | Arterial hypertensive patients with high and very high cardiovascular risk | 114                    | CAVI, AIx                               | CAVI and AIx were improved by rosuvastatin treatment, 12% and 17%, respectively. |
| Canepa et al., 2018 [74]        | Single-arm                            | Rosuvastatin                       | 5-10 mg/d   | 3 months        | Newly diagnosed heterozygous familial hypercholesterolemia       | 20                     | Aortic PWV, AIx, AIx75, and arterial BP | PWV significantly decreased.                                                     |
| Ikdahl et al., 2015 [75]        | Single-arm                            | Rosuvastatin                       | 20-40 mg/d  | 18 months       | Patients with inflammatory joint diseases                        | 85                     | Aortic PWV, AIx                         | None of the arterial stiffness indices substantially altered.                     |
| Ikdahl et al., 2016 [76]        | Single-arm                            | Rosuvastatin                       | 20-40 mg/d  | 18 months       | Patients with inflammatory joint diseases                        | 89                     | Aortic PWV, AIx                         | AIx and aPWV were noticeably decreased.                                            |
| Timár et al., 2013 [77]         | Single-arm                            | Rosuvastatin                       | 20 mg/d     | 6 months        | Patients with systemic sclerosis                                  | 28                     | Aortofemoral PWV, carotid-femoral PWV CAVI | Arterial stiffness was not affected by the treatment.                              |
| Deguchi et al., 2014 [78]       | Single-arm                            | Rosuvastatin                       | 5 mg/d      | 12 months       | Dyslipidemic patients with cerebral infarction                    | 17                     | CAVI                                    | CAVI showed no substantial change after rosuvastatin therapy.                     |
| Author, year | Study design | Interventions | Statin dose | Duration | Population | Number of participants | Method of arterial stiffness assessment | Main finding |
|-------------|--------------|---------------|-------------|----------|------------|------------------------|----------------------------------------|-------------|
| Pirro et al., 2007 [79] | Randomized open-label | 1. Rosuvastatin (with low-fat diet) 2. Low-fat diet | 10 mg/d | 4 weeks | Patients with primary hypercholesterolemia | 71 | Aortic PWV | PWV decreased significantly with rosuvastatin compared to baseline. |
| Igase et al., 2012 [80] | Randomized, open-label | 1. Rosuvastatin (+diet and exercise therapy) 2. Diet and exercise therapy | 2.5 mg/d | 3 months 12 months | Postmenopausal women with dyslipidemia | 51 | baPWV, SI | Arterial stiffness markedly reduced compared to placebo after 3 and 12 months. |
| Ott et al., 2012 [81] | Randomized, double-blind, placebo-controlled, crossover | 1. Rosuvastatin 2. Placebo | 10 mg/d | 42 days | Hypercholesterolic patients | 29 | AIx, AIx75 | Ab75 was substantially lower compared to the placebo. |
| Mitsiou et al., 2018 [82] | Randomized | Rosuvastatin | 1. Low dose (5 mg/d) 2. High dose (20-40 mg/d) | 6 months | Patients with optimally controlled arterial hypertension | 40 | Aortic PWV, AIx75 | Arterial stiffness significantly improved with both treatments, but the high dose was more effective on PWV improvement. |
| Wang et al., 2014 [83] | Clinical trial | 1. Rosuvastatin 2. Nonstatin treatment | 10 mg/d | 12 weeks | Hyperlipidemic patient without hypertension | 120 | Radial artery AIx, baPWV | Rosuvastatin significantly decreased the levels of baPWV and radial AIx compared to baseline. |
| Tam et al., 2011 [84] | Randomized, double-blind placebo-controlled | 1. Rosuvastatin 2. Placebo | 10 mg/d (starting with 5 mg/d) | 12 months | Patients with rheumatoid arthritis | 42 | AIx | No noticeable change was observed. |
| Kim et al., 2018 [85] | Single-arm | Pitavastatin | 4 mg/d | 3 months | Hypercholesterolemic patients | 48 | Stiffness index-β2, SI | Stiffness index-β2 improved substantially. |
| Miyashita et al., 2009 [86] | Single-arm | Pitavastatin | 2 mg/d | 12 months | Type-2 diabetics patients with hyperlipidemia | 45 | CAVI | CAVI was reduced significantly. |
| Muramatsu et al., 1997 [87] | Single-arm | Pravastatin | 10 mg/d | 6 months | Hypercholesterolemic patients | 59 | PWV | PWV showed significant improvement in patients with a higher reduction in TC (≥15%) compared with the group with <15% reduction in TC. Reduction in PWV remained over a 5-year period. |
| Matsuo et al., 2005 [88] | Quasiexperimental | 1. Pravastatin 2. Control (healthy untreated volunteers) | 10 mg/d | 6 months | Hyperlipidemic patients | 35 | baPWV | baPWV significantly reduced by the treatment. |
| Duan et al., 2014 [89] | Quasiexperimental | 5 or 10 mg/d | 6 months | Children with medium to giant coronary | 27 | SI | No significant change was observed. |
| Author, year | Study design | Interventions | Statin dose | Duration | Population | Number of participants | Method of arterial stiffness assessment | Main finding |
|-------------|--------------|---------------|-------------|----------|------------|------------------------|--------------------------------------|--------------|
| Forbat et al., 1998 [90] | Single-arm | 1. Pravastatin 2. Control (healthy untreated children) | 40 or 80 mg/d | 1 year | Hypercholesterolemic patients | 60 | Aortic compliance | There was a marked rise in aortic compliance. |
| Ersoy et al., 2014 [91] | Single-arm | Fluvastatin | 80 mg/d | 6 months | Dyslipidemic renal transplant recipients | 14 | Large and small vessel compliances | Arterial compliance parameters did not change. |
| Ichihara et al., 2002 [92] | Randomized, double-blind placebo-controlled | 1. Fluvastatin 2. Placebo | 20 mg/d | 3 months 6 months | Diabetic ESRD patients with normal serum lipid levels | 22 | PWV | Fluvastatin significantly improved PWV compared with placebo after 6 months. |
| Lunder et al., 2011 [93] | Randomized, double-blind placebo-controlled | 1. Fluvastatin 2. Placebo | 10 mg/d | 14 days 30 days | Apparently healthy, middle-aged males | 50 | PWV, SI | PWV and SI significantly improved by the intervention. |
| Yokoyama et al., 2005 [94] | Randomized, open-label | 1. Fluvastatin 2. Diet | 40 mg/d | 12 months 3, 6, and 12 months and 2, 3, 4, and 5 years | Hyperlipidemic patients | 40 | SI, baPWV | PWV significantly increased in the control group, while decreased in fluvastatin group. |
| Hongo et al., 2008 [95] | Randomized, single-blind | 1. Fluvastatin 2. Bezaflibrate | 20–40 mg/d | 12 months | Patients with CAD and hyperlipidemia | 93 | baPWV | After 12 months, baPWV decreased substantially in fluvastatin-treated group compared to bezafibrate-treated group and remained significant until the end of the study. |
| Drapkina et al., 2012 [96] | Randomized | 1. Atorvastatin 2. Rosuvastatin | — | 5 weeks | Patients with arterial hypertension and dyslipidemia | 82 | AIx, AIx75, RI, and SI | A marked reduction was observed in SI. |
| Simsek et al., 2014 | Clinical trial | 1. Atorvastatin 2. Rosuvastatin | 20 mg/d 10 mg/d | 12 months | Hyperlipidemic patients | 108 | PWA parameters | Rosuvastatin showed a greater ameliorative effect on vascular stiffness than the atorvastatin. |
| Liu et al., 2013 [97] | Randomized controlled | 1. Rosuvastatin 2. Simvastatin/ezetimibe | 10 mg/d | 8 weeks | Patients with coronary artery disease | 36 | baPWV | baPWV was significantly decreased in the rosuvastatin group compared to the simvastatin/ezetimibe group. |
| Ilyukhin et al., 2005 [98] | Clinical trial | 1. Atorvastatin 2. Simvastatin | 10 mg/g 20 mg/d | 6 months | Patients with ischemic heart disease | 38 | PWV | Atorvastatin and simvastatin treatment was associated with -10.05% and -4.66% reduction in PWV. |
| Hongo et al., 2011 [99] | Randomized, open-labeled | 1. Rosuvastatin 2. Fluvastatin | 2.5–5 mg/d 20–40 mg/d | 3 months 6 months 12 months | High-risk CVD patients with dyslipidemia | 75 | baPWV | Both treatments significantly improved arterial elasticity after 12 months, and rosuvastatin was more effective. |
| Author, year          | Study design       | Interventions                                      | Statin dose | Duration | Population                        | Number of participants | Method of arterial stiffness assessment | Main finding                                                                 |
|----------------------|--------------------|----------------------------------------------------|-------------|----------|-----------------------------------|------------------------|-----------------------------------------|--------------------------------------------------------------------------------|
| Ichihara et al., 2005 [100] | Randomized, single-blind | 1. Simvastatin  
2. Fluvastatin  
3. Pravastatin  
4. Nonstatin antihyperlipidemic drug | 5 mg/d  
20 mg/d  
10 mg/d | 3 months  
6 months  
9 months  
12 months | Hyperlipidemic hypertensive patients | 85 | baPWV | After 12 months, fluvastatin treatment was associated with a significant reduction in baPWV. |

AIX, augmentation index; AIX75, augmentation index normalized to 75 bpm; AP, augmentation pressure; CAVI, cardio-ankle vascular index; PWA, pulse-wave analysis; PWV, pulse-wave velocity; baPWV, brachial-ankle PWV; RI, reflection index; SI, stiffness index; Tr, transit time of the reflected wave; BP, blood pressure; COPD, chronic obstructive pulmonary disease; CAD, coronary artery disease; CKD, chronic kidney disease; ESRD, end-stage renal disease; CVD, cardiovascular disease.
change from baseline (placebo group), \( P = 0.007 \), but at the end of 18 months, no significant difference was observed between the groups (-1.1% change from baseline (statin group) vs. 0.2% change from baseline (placebo group), \( P = 0.3 \)) [42]. Thus, Gepner et al. suggested that the decrease in aortic stiffness due to simvastatin treatment was only transient. Along these lines showing little benefit to simvastatin treatment as it pertains to aortic stiffness, Balaguer et al. conducted a double-blind, randomized, placebo-controlled trial with 18 chronic obstructive pulmonary disease (COPD) patients. The patients were divided to receive either placebo or simvastatin (40 mg/day), for 12 weeks. At the end of the trial, no significant changes were observed in parameters used to assess arterial stiffness, including PWV and Alx [43]. As further validation of the results obtained by Balaguer et al. mentioned directly above, Cash et al. conducted a single-blind, randomized controlled trial with 13 primary biliary cirrhosis patients with hypercholesterolemia. The 13 patients were randomly assigned to two groups: the first group received 20 mg/day simvastatin, while the second group received placebo at the same dose. After 12 months, these authors found no significant changes in parameters used to assess arterial stiffness (aortic PWV, Alx75, and Tr) between the two groups [44].

3. Atorvastatin

To evaluate the efficacy of atorvastatin on improving arterial stiffness, several studies have been performed, which can be divided into single-arm and two-arm trials.

3.1. Single-Arm Trials. In a study by Wang et al. it was reported that six months of atorvastatin treatment (20 mg/day) resulted in a significant reduction in baPWV (10.63%, \( P < 0.01 \)) in hypertensive patients [45]. Additionally, it was previously reported that atorvastatin administration (10 mg/day) for 6 months decreased the femoral-ankle PWV of 22 patients with type-2 diabetes and hypercholesterolemia (from 1123 ± 162 cm/s to 1073 ± 142 cm/s, \( P = 0.019 \)). However, in this study, other indices of vascular elasticity (i.e., heart-carotid, heart-brachial, and heart-femoral PWV) did not change with atorvastatin treatment [46]. In another study, 20 mg/day atorvastatin was given to 37 systemic lupus erythematosus female patients for 8 weeks. At the end of the treatment, aortic PWV was unaffected by the treatment, but a significant improvement was observed in patients with baseline pathological arterial stiffness, which was maintained for six months following cessation of atorvastatin treatment [47].

In a trial of rheumatoid arthritis patients, Alx markedly decreased after 6 and 12 weeks of daily intake of 20 mg atorvastatin. Those participants with the highest scores for disease severity demonstrated the maximum improvement in arterial stiffness [48]. Ratchford et al. reported that 30 days of atorvastatin therapy (80 mg/day) in stroke-free and statin-naïve subjects led to a significant improvement in the stiffness index (SI) [49]. Similarly, receiving 20 mg/day atorvastatin for 2 years in patients with hypercholesterolemia led to a significant amelioration in aortic SI by 14% (\( P = 0.019 \)) [50].

In two trials conducted by Leibovitz et al., the effect of atorvastatin on arterial compliance was evaluated. The first study showed that after 20 weeks of statin treatment (mean dose: \( 16 \pm 1.6 \) mg/day), small artery compliance substantially increased in 17 patients with severe hypercholesterolemia [51]. The results of the second study indicated that after adding atorvastatin (10 or 20 mg/day, according to the investigator’s decision) to amlodipine for a 3-month period, small artery compliance noticeably increased in hypertensive, hyperlipidemic patients [52]. In addition, following 6 months of treatment with 40 mg/day atorvastatin, small and large artery compliance in 33 patients with coronary artery disease (CAD) was significantly improved [53]. To evaluate the protective effect of a high, single dose of atorvastatin against arterial stiffening, Tulmaç et al. conducted a trial with 30 dyslipidemic patients without atherosclerosis. In this trial, 24 hours after ingestion of atorvastatin (80 mg), arterial stiffness parameters (SI and RI) were found not to be altered [54]. Finally, following 12 months of atorvastatin treatment (10 mg/day) in 30 hypercholesterolemic subjects, no substantial changes were observed in the baPWV [55].

3.2. Two-Arm Trials. In a prospective, nonrandomized study, 79 subjects with type-2 diabetes and dyslipidemia were recruited to evaluate whether 12 months of the Mediterranean diet alone (diet group), or 10 mg atorvastatin plus the Mediterranean diet, would affect arterial stiffness parameters. The atorvastatin-treated group showed a significant improvement in aortic PWV compared to baseline and the subjects in the “diet group.” Additionally, carotid-radial PWV showed a reduction, but not a statistically significant trend during assessments at 3, 6, and 12 months [56]. In another study, 63 CAD patients with hyperlipidemia received either 10 mg of atorvastatin daily plus a low-fat diet or a low-fat diet alone (diet group). After 6 months, the PWV values (carotid-femoral, carotid-radial, and carotid-distal) for the subjects in the atorvastatin plus low-fat diet group were markedly decreased compared to baseline values and corresponding values for the patients contained in the “diet group” [57].

In a randomized study, Huang et al. reported that 20 mg/day atorvastatin in combination with levamlodipine besylate in hypertensive patients with dyslipidemia and quantifiable biomarkers indicating an overall inflammatory environment exhibited a markedly improved PWV compared to the group treated with levamlodipine besylate only following 8 weeks of intervention (\( P < 0.05 \)) [58]. In another different randomized, double-blind, placebo-controlled study, indices of vascular stiffness, including aortic PWV, SI, and arterial compliance (but not brachial PWV), were assessed following 12 weeks of daily intake of atorvastatin (80 mg) in overweight and obese middle-aged and older adults. This particular study showed a significant improvement in the indices of vascular stiffness for subjects taking atorvastatin when compared to those subjects in the placebo group [59]. In a similar design, Kanaki et al. showed that administration of atorvastatin at the dose of 10 mg/day for 6 months in hypertensive and hypercholesterolemic patients led to a substantial decrease in the values of aortic PWV,
normalized PWV (for mean blood pressure (MBP) and heart rate), AIx75, and AP compared to these same parameters for patients in the placebo group [60]. In another parallel, double-blind clinical trial, 142 hypertensive patients were randomized to receive atorvastatin (10 mg/day), or placebo, for 12-18 months. At the end of the study, atorvastatin treatment was associated with a significant improvement in arterial stiffness parameters (carotid AIx, carotid AP, and RI from the body) compared to these same parameters for patients in the placebo group [61].

In a randomized, open-label trial lasting 12 months, 51 male patients with type-2 diabetes and microalbuminuria were divided into two groups according to the treatment dose of atorvastatin (10 or 80 mg/day). At 3- and 12-month follow-ups, carotid-femoral PWV improved in both groups (P < 0.001 from baseline), although there was no difference between the 10 mg or 80 mg dose (i.e., there was no dose-dependent effect) between the groups [62]. In a similar study, 51 subjects with moderate cholesterolemia (total cholesterol: 200-250 mg/dl) were randomly assigned to orally ingest different doses of atorvastatin (10 or 40 mg/day). Carotid-radial PWV was measured at the start of the study (baseline), and again at one and eight weeks. The results of this study showed that the high-dose treatment (40 mg/day) significantly decreased PWV after one and eight weeks, and the change in the PWV at eight weeks was significantly different between the two groups [63].

In one double-blind, cross-over trial, administration of atorvastatin 40 mg/day for 4 weeks in patients with ischemic heart failure was associated with a substantial reduction of AIx75 compared with baseline, as well as Aix75 values for patients who received 10 mg/day atorvastatin (−2.88 ± 6.38% vs. −0.86 ± 4.09%, P = 0.048) [64]. Furthermore, in a different double-blind trial, 20 hypercholesterolemic patients were randomly assigned to receive either 20 or 80 mg/day atorvastatin for 3 months. At the end of the intervention, the distensibility coefficient increased significantly in both groups (P < 0.001), but there was not a significant difference in the distensibility coefficient between the groups [65].

In a randomized trial involving atorvastatin treatment (10 mg/day) in 57 normotensive, normolipidemic individuals with type-2 diabetes, it was reported that atorvastatin therapy significantly lowered the values of baPWV compared to baseline (1712.03 ± 349.9 cm/s vs. 1558.81 ± 303.26 cm/s); however, this alteration was not statistically significant in the placebo group (1692.03 ± 425.15 cm/s vs. 1636.78 ± 425.1 cm/s) [66]. Kabaklić and Fras, in a double-blind, placebo-controlled clinical trial, evaluated atorvastatin treatment and arterial stiffness in patients with angina pectoris and a normal coronary angiogram. Patients were randomly divided to receive 20 mg atorvastatin, or matched placebo. After a 6-month intervention, although AIx75 significantly improved in the atorvastatin group, there was no noticeable difference observed between the groups (-30.77% placebo group, P = 0.077) [67].

Fassett et al. reported that there was a rising trend in aortic PWV in patients with chronic kidney disease (CKD) even after atorvastatin administration (10 mg/day) for 3 years. In this investigation, although the rising trend of aortic PWV was 41% slower in the atorvastatin-treated group, no significant difference was detected between the groups. Moreover, other arterial parameters (AIx and arterial pressure) were unaffected by the intervention [68]. Joyeux et al. also conducted a randomized, double-blind, parallel clinical trial and reported that a daily intake of 40 mg atorvastatin, or matched placebo, for 12 weeks did not affect aortic PWV of subjects suffering from obstructive sleep apnea syndrome [69]. Additionally, in a cross-over, placebo-controlled study, the effect of daily intake of atorvastatin (40 mg/day) was assessed in first-degree relatives of patients with premature coronary artery disease and endothelial dysfunction. After a 6-week intervention, no significant effect on AIx was noted [70].

Lastly, in another double-blind, placebo-controlled trial, 23 patients with hypertension and hypercholesterolemia were recruited to receive either 10 mg/day atorvastatin or placebo, for 12 weeks. At the end of the 12-week intervention, indices of arterial stiffness (aortic PWV, carotid AIx) were not modified as a result of the intervention, even after adjustment for age, gender, and basal mean blood pressures (P ≥ 0.05) [71]. In a similar double-blind study, 325 subjects with concomitant hypertension and dyslipidemia were assigned to orally ingest either 10 mg/day atorvastatin or placebo. After 8 weeks of treatment, no statistically significant difference in compliance of small and large arteries was detected [72].

4. Rosuvastatin

Rosuvastatin, as another member of the statin family of drugs that inhibit HMG-CoA reductase, has been evaluated in several arterial stiffness trials.

4.1. Single-Arm Trials. In one particular study, rosuvastatin was administered to 114 patients with arterial hypertension and classified as having high and very high cardiovascular risk. These were patients who did not reach their target level of cholesterol after 1 year of atorvastatin treatment (20 mg/day). Rosuvastatin was initiated at a dose of 10 mg/day and then titrated upward to 20 and 40 mg/day if the cholesterol goal was not obtained. After 1.5 years of treatment, CAVI and AIx were improved by 12% and 17%, respectively [73]. Another investigation assessed the effect of 5-10 mg/day rosuvastatin treatment on arterial stiffness markers (aortic PWV, AIx, AIx75, and arterial pressure) in 20 subjects with newly diagnosed, heterozygous familial hypercholesterolemia. This investigation lasted for 3 months, and ultimately, aortic PWV showed a significant improvement (from 8.30 ± 1.4 to 7.13 ± 0.97 m/sec, P < 0.0001), even after adjusting for mean blood pressure and heart rate (P < 0.0001) [74].

In two studies, Ikdahl et al. assessed the efficacy of rosuvastatin treatment (20-40 mg/day) on parameters of arterial stiffness in patients with inflammatory joint diseases. In the first study, the values of aortic PWV and AIx did not change after 18 months of rosuvastatin treatment (P value: 0.78 and 0.06, respectively). In this study, flow-mediated dilation (FMD), an endothelial dysfunction index, was significantly
improved, and the reduced A1x was significantly correlated with ΔFMĐ ($P < 0.05$) [75]. In the second study, after 18 months of rosuvastatin intervention, the aortic PWV, A1x, and brachial BP were significantly decreased. Additionally, the baseline A1x and aortic PWV values (greater arterial stiffness) were associated with a more marked reduction during the study ($P < 0.001$) [76].

In a final one-arm study, 28 patients with systemic sclerosis were enrolled to receive 20 mg rosuvastatin daily for 6 months. At the end of this trial, none of the vascular stiffness parameters (aortofemoral and carotid-femoral PWV) was improved [77]. Lastly, Deguchi et al. determined that there was no significant improvement in CAVI of dyslipidemic patients with cerebral infarction who received 5 mg/day rosuvastatin for 12 months [78].

4.2. Two-Arm Trials. In a randomized, open-label study, seventy-one patients with primary hypercholesterolemia were divided into two groups; the first group received 10 mg/day rosuvastatin with a low-fat diet, and the second group received only a low-fat diet. This intervention lasted for 4 weeks, and, at the conclusion of the study, the aortic PWV showed a significant improvement in the rosuvastatin group (from 9.5 ± 1.9 m/s to 7.8 ± 1.5 m/s, $P = 0.02$), while no substantial change was detected in the low-fat diet group (from 9.2 ± 2.1 m/s to 8.8 ± 1.9 m/s) [79]. In another randomized, open-label study, Igase et al. showed that administration of rosuvastatin (2.5 mg/day, which was accompanied by diet and exercise) in postmenopausal women with dyslipidemia for 3 and 12 months significantly decreased the levels of baPWV and SI compared to the control group (diet and exercise alone) [80]. In yet another double-blind, placebo-controlled, cross-over study, 29 hypercholesterolemic patients were randomized to orally ingest either rosuvastatin (10 mg/day) or placebo, for 42 days. After the intervention, the A1x75 significantly improved compared to the placebo group [81].

To evaluate the efficacy of low dose (5 mg/day) versus high dose (20–40 mg/day) of rosuvastatin on arterial elasticity, 40 patients with optimally controlled arterial hypertension were enrolled and followed for 6 months. At the end of the study, aortic PWV and A1x75 improved in both groups, and the high dose was more effective in reducing the PWV [82]. Additionally, a study was conducted wherein 120 hyperlipidemic subjects received either 10 mg/day rosuvastatin or no statin. After 12 weeks of drug intervention, the values of baPWV and radial A1x significantly improved in the rosuvastatin-treated group (baPWV: 1340 ± 177 vs. 1477 ± 159 cm/s; radial A1x: 44 ± 13% vs. 57 ± 15%; $P < 0.01$ and $P < 0.05$), while no substantial changes were observed in the nonstatin treatment group [83].

Lastly, in a randomized, double-blind, placebo-controlled clinical trial, 42 patients with rheumatoid arthritis received rosuvastatin treatment (10 mg/day) for 1 year. However, no significant changes were observed in the values of A1x [84].

5. Pitavastatin

With regard to the effects of pitavastatin on arterial stiffness, we identified two studies in the literature. In the first study, forty-eight hypercholesterolemic patients received pitavastatin 4 mg/day, and arterial stiffness parameters (stiffness index–β2 and SI) were assessed at baseline and at a 3-month follow-up. At the end of the study, the stiffness index–β2 significantly improved in patients taking 4 mg/day of pitavastatin [85]. In the second study, Miyashita et al. reported that after 12 months of pitavastatin treatment (2 mg/day), CAVI was markedly reduced (from 9.54 to 8.91) in 45 patients with type-2 diabetes and hyperlipidemia [86].

6. Pravastatin

Only a few studies have examined the efficacy of pravastatin on arterial stiffness parameters. In one such study, 59 hypercholesterolemic patients were recruited to orally ingest pravastatin (10 mg/day) for 6 months. At the end of the study, the PWV significantly improved in those patients who were documented to have a higher reduction in TC (≥15%). In addition, PWV reduction remained over a 5-year period [87].

In another study, pravastatin treatment (10 mg/day) for 6 months in 15 hyperlipidemic patients significantly improved baPWV, while the values increased, but were not statistically significant, in the healthy control volunteers [88]. Lastly, Duan et al. reported that pravastatin therapy (5-10 mg/day) for six months improved endothelial dysfunction in 13 children with medium to giant coronary aneurysms due to Kawasaki disease, although it did not affect the value of SI when compared to this same parameter in healthy control children [89].

7. Fluvastatin

Fluvastatin is another member of the statin drug class and has been used to treat arterial wall rigidity in a number of trials.

7.1. Single-Arm Trials. To evaluate the impact of fluvastatin on arterial elasticity, 60 hypercholesterolemic subjects with, or without coronary artery disease, received fluvastatin at a dose of either 40 or 80 mg/day, based on the percent of cholesterol reduction during the first 12 weeks. In this study, aortic compliance markedly improved following 1 year of statin treatment (from 11.72 ± 5.4 to 16.49 ± 7.3 μm/mHg, $P < 0.0001$) [90]. However, Ersoy et al. reported that 80 mg/day fluvastatin administration for 6 months did not alter large and small vessel compliance in 14 dyslipidemic renal transplant recipients [91].

7.2. Two-Arm Trials. As it pertains to two-arm trials evaluating the potential benefit of fluvastatin for arterial stiffness, one double-blind, placebo-controlled trial enrolled 22 diabetic ESRD patients with normal serum lipid levels. These patients were randomly assigned to orally ingest fluvastatin (20 mg/day), or placebo, for 6 months. During the study, the PWV exhibited a progressive reduction in the fluvastatin group and a progressive elevation in the placebo group, and ultimately (at 6 months), the difference between the groups was statistically significant [92]. In another randomized, double-blind, placebo-controlled trial, fluvastatin administration
at a dose of 10 mg/day for 14 and 30 days in apparently healthy, middle-aged males substantially improved arterial stiffness parameters (PWV and SI) compared with the placebo group [93]. In this trial, five months after discontinuation of fluvastatin treatment, the SI was still markedly improved when compared to baseline values ($P = 0.01$). In addition, there was an investigation in which forty hyperlipidemic subjects were enrolled in an open-label study and were randomized to receive either 40 mg/day fluvastatin or diet (control group), for 12 months. In this investigation, the baPWV noticeably decreased in the fluvastatin group, while it increased in the control diet group. Moreover, fluvastatin treatment led to a significant improvement in the SI when compared to baseline values [94]. Finally, in a randomized, single-blind trial, 93 subjects with CAD and hyperlipidemia were assigned to receive either fluvastatin (20-40 mg/day) or bezafibrate (200-400 mg/day) for 5 years. In this trial, it was noted that the fluvastatin-treated group showed a decreasing trend in the values of the baPWV, while this trend was shown to increase in the bezafibrate-treated group. Importantly, the difference in the values of the baPWV between the groups was statistically significant after 12 months [95].

8. Comparison of Different Statins

In one particular study, 82 patients with arterial hypertension and dyslipidemia were divided to receive either atorvastatin or rosuvastatin. After five weeks of intervention, a significant reduction in SI values and a nonsignificant improvement in AIX and RI were observed in both groups [96].

There have been other trials in which the efficacy of one statin was compared with another statin as it pertains to arterial stiffness parameters. For example, in one controlled trial, 36 participants with coronary artery disease were randomized to orally ingest either rosuvastatin (10 mg daily) or simvastatin/ezetimibe (10/10 mg/day) for 8 weeks. In this trial, the value of the baPWV did not change in the simvastatin/ezetimibe group, while it improved significantly in the rosuvastatin-treated group when compared with baseline values (from 1772 ± 430 cm/s to 1603 ± 398 cm/s) and baPWV values for the simvastatin/ezetimibe group [97]. In another clinical trial conducted by Ilyukhin et al., 38 ischemic heart disease patients were administered either 10 mg/dayatorvastatin or 20 mg/day simvastatin, for 6 months. At the end of the study, atorvastatin and simvastatin treatment resulted in a 10.05% and 4.66% improvement in PWV, respectively [98].

In addition, an open-label clinical study was conducted that involved 75 patients with high-risk cardiovascular disease and dyslipidemia. The patients were randomized to take either rosuvastatin (2.5-5 mg/day) or fluvastatin (20-40 mg/day), for 12 months. In this trial, statin treatment significantly improved the values of baPWV, but rosuvastatin was more effective than fluvastatin [99]. Moreover, in a randomized, single-blind trial, the effect of daily oral administration of 5 mg simvastatin, 20 mg fluvastatin, 10 mg pravastatin, and a nonstatin antihyperlipidemic drug was assessed in 85 hyperlipidemic, hypertensive subjects. At the end of the 12-month study, only fluvastatin treatment in hyperlipidemic, hypertensive subjects led to a significant reduction in the values of baPWV when compared to baseline values and corresponding values of baPWV for the other groups [100].

9. Mechanism

The results of meta-analyses have suggested that the effect of statins on arterial elasticity appears to be due, at least in part, to their pleiotropic effects, which are independent of changes in blood pressure, lipid profile, and even statin type (Figure 1) [101, 102]. As mentioned above, in addition to their lipid-lowering properties, statins also have pleiotropic effects, such as anti-inflammatory, antiproliferative, antioxidant, and antithrombotic properties. Additionally, statins reduce endothelial dysfunction, improve vascular and myocardial remodeling, and stabilize atherosclerotic plaque [102–104].

The principal mechanism underlying the pleiotropic effects of statins appears to be inhibition of mevalonate synthesis, and subsequently, inhibition of Rho isoprenylation and its downstream target, Rho kinase (ROCK) [102, 103]. Binding of isoprenylated Rho to ROCK leads to ROCK activation, which, in turn, results in a reduction in the half-life of eNOS mRNA and NO production. Thus, statins can induce production of NO by inhibition of the Rho/ROCK pathway [5, 105–108]. Additionally, although it is not clearly understood at this time, it has been demonstrated that statins stimulate activity in the PI3K/AKT pathway, which ultimately leads to eNOS phosphorylation and NO production [109, 110]. Importantly, and as mentioned above, statins can indirectly inhibit the Rho/ROCK pathway, which accelerates the activity of the PI3K/AKT pathway and NO production [111].

In addition, administration of statins is associated with the regulation of paracrine mediators, including angiotensin II and endothelin [3]. In vitro studies have indicated that synthesis of endothelin-1 (ET-1), a potent vasoconstrictor and mitogenic peptide that enhances the tone of vascular smooth muscle cells (VSMCs), and the mRNA expression of its precursor, pre-proET-1, decrease following statin treatment. The reduction in the expression of pre-proET-1 appears to be related to the capacity of the statin to suppress Rho GTPases [112–114]. Angiotensin II (AII) is a vasoconstrictor hormone that contributes to vascular stiffening via an increase in collagen formation, vascular hypertrophy, matrix remodeling, oxidant stress, and decrease in elastin synthesis and NO production [3]. Several studies have revealed that statin therapy downregulates the expression of angiotensin II receptor type 1 (AT1) and mitigates the biological function of Ang II [115–118]. In fact, there is evidence that statins reduce NAD(P)H oxidase activity, a multicomponent enzyme complex that is responsible for ROS generation, by suppressing the geranylation of Rac GTPase and downregulating other NAD(P)H oxidase subunits [118–122].

Another mechanism of statin action is related to the regulation of tetrahydrobiopterin (BH4) concentration, which is an essential cofactor of eNOS. Statins can increase the availability of BH4 either by preventing the oxidation of BH4 to...
BH3 radical or by reducing C-reactive protein (CRP), an inflammatory marker that can block the activity of the rate-limiting enzyme GTP cyclohydrolase-1, which is needed for the synthesis of BH4 [123]. Additionally, it has been demonstrated that hypercholesterolemia reduces the activation of eNOS by increasing caveolin expression and that statin therapy leads to a suppression in the increased expression of caveolin, which subsequently improves NO synthesis [124–126].

Lastly, previous studies have shown that statins can reduce arterial stiffness by several other mechanisms, which include (1) inhibition in the migration of monocytes [127], (2) modification of the inflammatory response of macrophages and endothelial cells [128], (3) downregulation in ICAM-1 expression [118], (4) reduction in elastin degradation (i.e., greater elastin in statin treated animals) [129], (5) reduction in collagen formation (i.e., since collagen imparts stiffness to the myocardial wall) [119, 130, 131], (6) inhibition of atherosclerosis progression, and (7) inhibition of VSMC proliferation [132].

10. Conclusion

In recent years, arterial stiffness as an early marker of cardiovascular disease and mortality has attracted the attention of a large number of investigators. It has been reported that each 47 cm/s increase in pulse-wave velocity is associated with a 5-year increase in arterial age [133], and 1 m/s increase is associated with a 13% increase in lethal cardiovascular events death [134]. Therefore, finding an effective approach to improve vascular elasticity is a priority. Several studies have been performed to assess the efficacy of HMG-CoA reductase inhibitors in improving arterial stiffness. Although several studies showed positive effects of statins on vascular elasticity, some others reported conflicting results. This discrepancies may be due to small sample size, heterogeneous populations, short durations of follow-up, absence of a placebo group, inadequate dose of statins, and the lack of controlling for potential confounding factors. Considering the statins’ pleiotropic effects, to provide mechanistic perspective about the role of statins on vascular elasticity, concomitant assessment of antioxidant markers and inflammatory parameters such as high-sensitivity C-reactive protein could have been helpful for future studies.

Data Availability

This is a review article that does not include original data.

Conflicts of Interest

The authors declare no conflict of interest.

References

[1] A. Albu, S. Tache, N. Mavritsakis, and C. Potoră, “Physical exercise and arterial stiffness in elderly,” Palestrica of the Third Millennium Civilization & Sport, vol. 18, no. 2, pp. 100–104, 2017.

[2] Y. Chen, F. Shen, J. Liu, and G.-Y. Yang, “Arterial stiffness and stroke: de-stiffening strategy, a therapeutic target for
H. Shige, A. Dart, and P. Nestel, “The effect of statin therapy on plasma levels of von Willebrand factor antigen: systematic review and meta-analysis of randomised placebo-controlled trials,” *Thrombosis and Haemostasis*, vol. 115, no. 3, pp. 520–532, 2018.

S. M. L. Wallace, K. M. Mäki-Petäjä, J. Cheriyian et al., “Simvastatin prevents inflammation-induced aortic stiffening and endothelial dysfunction,” *British Journal of Clinical Pharmacology*, vol. 70, no. 6, pp. 799–806, 2010.

M. E. John, J. R. Cockcroft, T. M. McKeever et al., “Cardiovascular and inflammatory effects of simvastatin therapy in patients with COPD: a double-blind randomized controlled trial,” *International Journal of COPD*, vol. 10, pp. 211–221, 2015.

M. Kurpesa, T. Rechciński, E. Trzós, K. Wierzbowska, and M. Krzemiska-Pakula, “Effect of long term statin treatment on arterial compliance in primary hypertension,” *Folia Cardiologica*, vol. 11, no. 12, pp. 929–937, 2004.

K. D. Ballard, L. Lorson, C. M. White, P. D. Thompson, and B. A. Taylor, “Effect of simvastatin on arterial stiffness in patients with statin myalgia,” *Advances in Preventive Medicine*, vol. 2015, Article ID 351059, 6 pages, 2015.

H. Shige, A. Dart, and P. Nestel, “Simvastatin improves arterial compliance in the lower limb but not in the aorta,” *Atherosclerosis*, vol. 155, no. 1, pp. 245–250, 2001.

K. M. Mäki-Petäjä, A. D. Booth, F. C. Hall et al., “Ezetimibe and simvastatin reduce inflammation, disease activity, and aortic stiffness and improve endothelial function in rheumatoid arthritis,” *Journal of the American College of Cardiology*, vol. 50, no. 9, pp. 852–858, 2007.

S. Efrati, M. Averbukh, V. Dishy, M. Fayanzeno, L. Friedensohn, and A. Golik, “The effect of simvastatin, ezetimibe and their combination on the lipid profile, arterial stiffness and inflammatory markers,” *European Journal of Clinical Pharmacology*, vol. 63, no. 2, pp. 113–121, 2007.

A. D. Gepner, K. Lazar, C. V. Hulle, C. E. Korcarz, S. Asthana, and C. M. Carlsson, “Effects of simvastatin on augmentation index are transient: outcomes from a randomized controlled trial,” *Journal of the American Heart Association*, vol. 8, no. 20, p. e009792, 2019.

C. Balaguer, A. Peralta, A. Rios et al., “Effects of simvastatin in chronic obstructive pulmonary disease: results of a pilot, randomized, placebo-controlled clinical trial,” *Contemporary Clinical Trials Communications*, vol. 2, pp. 91–96, 2016.

W. J. Cash, S. O’Neill, M. E. O’Donnell et al., “Randomized controlled trial assessing the effect of simvastatin in primary biliary cirrhosis,” *Liver International*, vol. 33, no. 8, pp. 1166–1174, 2013.

J. Wang, J. Xu, C. Zhou et al., “Improvement of arterial stiffness by reducing oxidative stress damage in elderly hypertensive patients after 6 months of atorvastatin therapy,” *Journal of Clinical Hypertension*, vol. 14, no. 4, pp. 245–249, 2012.

K. Shinohara, T. Shoji, E. Kimoto et al., “Effect of atorvastatin on regional arterial stiffness in patients with type 2 diabetes mellitus,” *Journal of Atherosclerosis and Thrombosis*, vol. 12, no. 4, pp. 205–210, 2005.

R. Castejon, A. Castañeda, A. Sollet et al., “Short-term atorvastatin therapy improves arterial stiffness of middle-aged systemic lupus erythematosus patients with pathological pulse wave velocity,” *Lupus*, vol. 26, no. 4, pp. 355–364, 2017.

S. Van Doornum, G. McColl, and I. P. Wicks, “Atorvastatin reduces arterial stiffness in patients with rheumatoid arthritis,” *Annals of the Rheumatic Diseases*, vol. 63, no. 12, pp. 1571–1575, 2004.

E. V. Ratchford, J. Gutierrez, D. Lorenzo et al., “Short-term effect of atorvastatin on carotid artery elasticity: a pilot study,” *Stroke*, vol. 42, no. 12, pp. 3460–3464, 2011.

A. G. Kontopoulos, V. G. Athyros, A. N. Pehlivanidis, D. S. Demitriadis, A. A. Papageorgiou, and H. Boudoulas, “Long-term treatment effect of atorvastatin on aortic stiffness in hypercholesterolaemic patients,” *Current Medical Research and Opinion*, vol. 19, no. 1, pp. 22–27, 2008.

E. Leibovitz, N. Hazanov, R. Zimlichman, M. Sharorgorodsky, and D. Gavish, “Treatment with atorvastatin improves small artery compliance in patients with severe hypercholesterolemia,” *American Journal of Hypertension*, vol. 14, no. 11, pp. 1096–1098, 2001.

E. Leibovitz, M. Benishavilii, R. Zimlichman, A. Freiman, M. Sharorgorodsky, and D. Gavish, “Treatment with amlodipine andatorvastatin have additive effect in improvement of arterial compliance in hypertensive hyperlipidemic patients,” *American Journal of Hypertension*, vol. 16, no. 9, pp. 715–718, 2003.

C. Akgullu, B. Ozdemir, Y. Yilmaz, A. R. Kazazoglu, and A. Aydinlar, “Effect of intensive statin therapy on arterial elasticity in patients with coronary artery disease,” *Acta Cardiologica*, vol. 63, no. 4, pp. 467–471, 2008.

M. Tulmac, V. Simšek, E. Tireli et al., “Single high dose atorvastatin does not ameliorate endothelial function and large arterial stiffness in dyslipidemic patients without atherosclerosis,” *European Review for Medical and Pharmacological Sciences*, vol. 16, no. 6, pp. 824–828, 2012.

K. Ozaki, T. Kubo, R. Imaki et al., “The anti-atherosclerotic effects of lipid lowering with atorvastatin in patients with hypercholesterolemia,” *Journal of Atherosclerosis and Thrombosis*, vol. 13, no. 4, pp. 216–219, 2006.

P. Grigoropouloou, A. Tsentolouris, I. Eleftheriadou et al., “Effect of 12-month intervention with low-dose atorvastatin on pulse wave velocity in subjects with type 2 diabetes and dyslipidaemia,” *Diabetes & Vascular Disease Research*, vol. 16, no. 1, pp. 38–48, 2018.

X. Meng, L. Qie, Y. Wang, M. Zhong, and L. Li, “Assessment of arterial stiffness affected by atorvastatin in coronary artery disease using pulse wave velocity,” *Clinical and Investigative Medicine*, vol. 32, no. 6, pp. E238–E243, 2009.

H. Y. Huang, X. S. Pan, X. N. Huang et al., “Effects of atorvastatin on hypertension patients with dyslipidemia and body’s inflammatory response,” *Journal of Shanghai Jiaotong University (Medical Science)*, vol. 34, no. 11, pp. 1642–1646, 2014.

J. S. Orr, A. L. Dengo, J. M. Rivero, and K. P. Davy, “Arterial distiffening with atorvastatin in overweight and obese middle-aged and older adults,” *Hypertension*, vol. 54, no. 4, pp. 763–768, 2009.

A. I. Kanaki, P. A. Sarafidis, P. I. Georgianos et al., “Effects of low-dose atorvastatin on arterial stiffness and central aortic pressure augmentation in patients with hypertension and hypercholesterolemia,” *American Journal of Hypertension*, vol. 26, no. 5, pp. 608–616, 2013.

C. Manisty, J. Mayet, R. J. Tapp et al., “Atorvastatin treatment is associated with less augmentation of the carotid pressure wave,” *Circulation Research*, vol. 87, no. 1, pp. 55–59, 2000.
waveform in hypertension: a substudy of the anglo-scandinavian cardiac outcome trial (ASCOT),” *Hypertension*, vol. 54, no. 5, pp. 1009–1013, 2009.

[62] C. Davenport, D. T. Ashley, E. P. O’Sullivan et al., “The effects of atorvastatin on arterial stiffness in male patients with type 2 diabetes,” *Journal Diabetes Research*, vol. 2015, pp. 1–6, 2015.

[63] Y. S. Lee and K. S. Kim, “The short-term effect of atorvastatin on flow-mediated vasodilation, pulse wave velocity and carotid intima-media thickness in patients with moderate cholesterolemia,” *Korean Circulation Journal*, vol. 38, no. 3, pp. 144–151, 2008.

[64] D. Tousoulis, E. Oikonomou, G. Siassos et al., “Dose-dependent effects of short term atorvastatin treatment on arterial wall properties and on indices of left ventricular remodeling in ischemic heart failure,” *Atherosclerosis*, vol. 227, no. 2, pp. 367–372, 2013.

[65] Y. Karter, A. Çurgunlu, N. Ertürk, S. Vehid, I. Mihmanli, and F. Ayan, “Effects of low and high doses of atorvastatin on arterial compliance,” *Japanese Heart Journal*, vol. 44, no. 6, pp. 953–961, 2003.

[66] S. Mukherjee, P. Mukhopadhyay, K. Pandit, S. Mukherjee, and S. Chowdhury, “Atorvastatin improves arterial stiffness in normotensive normolipidaemic persons with type 2 diabetes,” *Journal of the Indian Medical Association*, vol. 106, no. 11, pp. 716–719, 2008.

[67] A. Kabakli and Z. Fras, “Moderate-dose atorvastatin improves arterial endothelial function in patients with angina pectoris & normal coronary angiogram: a pilot study,” *Archives of Medical Science*, vol. 13, no. 4, pp. 827–836, 2017.

[68] R. G. Fassett, I. K. Robertson, M. J. Ball, D. P. Geraghty, J. E. Sharman, and J. S. Coombes, “Effects of atorvastatin on arterial stiffness in chronic kidney disease: a randomised controlled trial,” *Journal of Atherosclerosis and Thrombosis*, vol. 17, no. 3, pp. 235–241, 2010.

[69] M. Joyeux-Faure, R. Tamisier, J. P. Baguet et al., “Response to statin therapy in obstructive sleep apnea syndrome: a multicenter randomized controlled trial,” *Mediators of Inflammation*, vol. 2014, 10 pages, 2014.

[70] S. J. Hong, H. J. Chang, S. Park et al., “Impact of atorvastatin treatment in first-degree relatives of patients with premature coronary artery disease with endothelial dysfunction: a double-blind, randomized, placebo-controlled crossover trial,” *Clinical Cardiology*, vol. 36, no. 8, pp. 480–485, 2013.

[71] J. Raison, A. Rudnichi, and M. E. Safar, “Effects of atorvastatin on aortic pulse wave velocity in patients with hypertension and hypercholesterolemia: a preliminary study,” *Journal of Human Hypertension*, vol. 16, no. 10, pp. 705–710, 2002.

[72] J. N. Cohn, D. J. Wilson, J. Neutel et al., “Concomitantly administered amiodipine and atorvastatin produces early improvements in arterial wall compliance in hypertensive patients with dyslipidemia,” *American Journal of Hypertension*, vol. 22, no. 2, pp. 137–144, 2009.

[73] V. P. Mikhin, Y. A. Zhilyaeva, V. V. Vorotyntseva et al., “Hypolipidemic and pleiotropic efficacy of rosuvastatin in arterial hypertension patients of high cardiovascular risk in long-term outpatient follow-up,” *Russian Journal of Cardiology*, vol. 140, no. 12, pp. 90–96, 2016.

[74] M. Canepa, N. Artom, P. Ameri et al., “Short-term effect of rosuvastatin treatment on arterial stiffness in individuals with newly-diagnosed heterozygous familial hypercholesterolemia,” *International Journal of Cardiology*, vol. 255, pp. 215–220, 2018.

[75] E. Ikäheimo, N. Hidala, S. Rollefstad et al., “Rosuvastatin improves endothelial function in patients with inflammatory joint diseases, longitudinal associations with atherosclerosis and arteriosclerosis: results from the RORA-AS statin intervention study,” *Arthritis Research and Therapy*, vol. 17, no. 1, 2015.

[76] E. Ikäheimo, S. Rollefstad, J. Hidala et al., “Sustained improvement of arterial stiffness and blood pressure after long-term rosuvastatin treatment in patients with inflammatory joint diseases: results from the rora-as study,” *PLoS One*, vol. 11, no. 4, e0153440, 2016.

[77] O. Timár, Z. Szekanecz, G. Kerekes et al., “Rosuvastatin improves impaired endothelial function, lowers high sensitivity CRP, complement and immunocomplex production in patients with systemic sclerosis - a prospective case-series study,” *Arthritis Research and Therapy*, vol. 15, no. 5, p. R105, 2013.

[78] I. Deguchi, Y. Horiuchi, T. Hayashi et al., “Effects of rosuvastatin on serum lipids and arteriosclerosis in dyslipidemic patients with cerebral infarction,” *Journal of Stroke and Cerebrovascular Diseases*, vol. 23, no. 8, pp. 2007–2011, 2014.

[79] P. Pirro, G. Schillaci, M. R. Mannarino et al., “Effects of rosuvastatin on 3-nitrotyrosine and aortic stiffness in hypercholesterolemia,” *Nutrition, Metabolism, and Cardiovascular Diseases*, vol. 17, no. 6, pp. 436–441, 2007.

[80] M. Igase, K. Kohara, Y. Tabara et al., “Low-dose rosuvastatin improves the functional and morphological markers of atherosclerosis in asymptomatic postmenopausal women with dyslipidemia,” *Menopause*, vol. 19, no. 12, pp. 1294–1299, 2012.

[81] C. Ott, M. P. Schneider, M. P. Schlaich, and R. E. Schmieder, “Rosuvastatin improves pulse wave reflection by restoring endothelial function,” *Microvascular Research*, vol. 84, no. 1, pp. 60–64, 2012.

[82] E. Mitsiou, C. Boutari, V. Kotsis et al., “Effect of low (5 mg) vs. high (20–40 mg) rosuvastatin dose on 24h arterial stiffness, central haemodynamics, and non-alcoholic fatty liver disease in patients with optimally controlled arterial hypertension,” *Current Vascular Pharmacology*, vol. 16, no. 4, pp. 393–400, 2018.

[83] P. Wang, Y. Liu, Z. Wang et al., “Effects of rosuvastatin on arterial stiffness in hyperlipidemia patients,” *National Medical Journal of China*, vol. 94, no. 31, pp. 2452–2454, 2014.

[84] L. S. Tam, E. Li, Q. Shang et al., “Effects of rosuvastatin on subclinical atherosclerosis and arterial stiffness in rheumatoid arthritis: a randomized controlled pilot trial,” *Scandinavian Journal of Rheumatology*, vol. 40, no. 6, pp. 411–421, 2011.

[85] C. Ha Kim, S. Wang, J. B. Park et al., “Assessing impact of high-dose pitavastatin on carotid artery elasticity with speckle-tracking strain imaging,” *Journal of Atherosclerosis and Thrombosis*, vol. 25, no. 11, pp. 1137–1148, 2018.

[86] Y. Miyashita, K. Endo, A. Saiki et al., “Effects of pitavastatin, a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor, on cardio-ankle vascular index in type 2 diabetic patients,” *Journal of Atherosclerosis and Thrombosis*, vol. 16, no. 5, pp. 539–545, 2009.

[87] J. Muramatsu, A. Kobayashi, N. Hasegawa, and S. Yokouchi, “Hemodynamic changes associated with reduction in total cholesterol by treatment with the HMG-CoA reductase
inhibitor pravastatin,” Atherosclerosis, vol. 130, no. 1-2, pp. 179–182, 1997.

[88] S. Matsu, Y. Nakamura, T. Yamada, Y. Uchida, I. Nakae, and M. Horie, “Effect of statin therapy on arterial stiffness in patients with hyperlipidemia: Shiga pravastatin atherosclerosis study (SHIPAS) group,” Journal of Applied Research., vol. 5, no. 2, pp. 397–401, 2005.

[89] C. Duan, Z. D. Du, Y. Wang, and L. Q. Jia, “Effect of pravastatin on endothelial dysfunction in children with medium to giant coronary aneurysms due to Kawasaki disease,” World Journal of Pediatrics, vol. 10, no. 3, pp. 232–237, 2014.

[90] S. M. Forbat, R. P. Naoumova, P. S. Sidhu et al., “The effect of cholesterol reduction with fluvastatin on aortic compliance, coronary calcification and carotid intimal-medial thickness: a pilot study,” Journal of Cardiovascular Risk, vol. 5, no. 1, pp. 1–10, 1998.

[91] A. Ersoy, S. Eryilmaz, A. Yildiz, C. Ersoy, B. Cuma Gul, and I. Baran, “Does fluvastatin improve arterial functions in dyslipidemic renal transplant recipients?,” Biomedical Research (India), vol. 25, no. 2, pp. 157–160, 2014.

[92] A. Ichihara, M. Hayashi, M. Ryuzaki, M. Handa, T. Furukawa, and T. Saruta, “Fluvastatin prevents development of arterial stiffness in haemodialysis patients with type 2 diabetes mellitus,” Nephrology, Dialysis, Transplantation, vol. 17, no. 8, pp. 1513–1517, 2002.

[93] M. Lunder, M. Janic, S. Habjan, and M. Šabović, “Subtherapeutic, low-dose fluvastatin improves functional and morphological arterial wall properties in apparently healthy, middle-aged males - a pilot study,” Atherosclerosis, vol. 215, no. 2, pp. 446–451, 2011.

[94] H. Yokoyama, M. Kawasaki, Y. Ito, S. Minatoguchi, and H. Fujiwara, “Effects of fluvastatin on the carotid arterial media as assessed by integrated backscatter ultrasound compared with pulse-wave velocity,” Journal of the American College of Cardiology, vol. 46, no. 11, pp. 2031–2037, 2005.

[95] M. Hongo, H. Tsutsui, E. Mawatari et al., “Fluvastatin improves arterial stiffness in patients with coronary artery disease and hyperlipidemia - a 5-year follow-up study,” Circulation Journal, vol. 72, no. 5, pp. 722–728, 2008.

[96] O. M. Drapkina, O. N. Korneeva, L. O. Palatkin, E. V. Zyatenkova, N. P. Balakhonova, and V. T. Ivashkin, “Rosuvastatin in patients with arterial hypertension and dyslipidemia: effects on microcirculation and pulse wave parameters,” Cardiovascular Therapy and Prevention (Russian Federation), vol. 11, no. 6, pp. 9–15, 2012.

[97] B. Liu, W. Che, H. Yan, W. Zhu, and H. Wang, “Effects of rosuvastatin vs. simvastatin/ezetimibe on arterial wall stiffness in patients with coronary artery disease,” Internal Medicine, vol. 52, no. 24, pp. 2715–2719, 2013.

[98] O. V. Iluykin, E. L. Kalganova, A. A. Babkin, and Y. M. Lopatin, “Changes of elastic properties of magistral arteries in patients with ischemic heart disease during treatment with atorvastatin and simvastatin,” Kardiologiya, vol. 45, no. 12, pp. 31–34, 2005.

[99] M. Hongo, S. Kumazaki, A. Izawa et al., “Low-dose rosuvastatin improves arterial stiffness in high-risk Japanese patients with dyslipidemia in a primary prevention group,” Circulation Journal, vol. 75, no. 11, pp. 2660–2667, 2011.

[100] A. Ichihara, M. Hayashi, Y. Koura, Y. Tada, Y. Kaneshiro, and T. Saruta, “Long-term effects of statins on arterial pressure and stiffness of hypertensives,” Journal of Human Hypertension, vol. 19, no. 2, pp. 103–109, 2005.

[101] L. D’elia, E. La Fata, A. Iannuzzi, and P. O. Rubba, “Effect of statin therapy on pulse wave velocity: a meta-analysis of randomized controlled trials,” Clinical and Experimental Hypertension, vol. 40, no. 7, pp. 601–608, 2018.

[102] A. Sahebkar, I. Pecin, E. Tedeschi-Reiner, G. Derosa, P. Maffioli, and Ž. Reiner, “Effects of statin therapy on augmentation index as a measure of arterial stiffness: a systematic review and meta-analysis,” International Journal of Cardiology, vol. 212, pp. 160–168, 2016.

[103] O. Bedi, V. Dhawan, P. Sharma, and P. Kumar, “Pleiotropic effects of statins: new therapeutic targets in drug design,” Naunyn-Schmiedeberg’s Archives of Pharmacology, vol. 389, no. 7, pp. 695–712, 2016.

[104] A. Rohilla, S. Rohilla, A. Kumar, M. U. Khan, and A. Deep, “Pleiotropic effects of statins: a boulevard to cardioprotection,” Arabian Journal of Chemistry, vol. 9, pp. S21–S27, 2016.

[105] P. Dilaveris, G. Giannopoulos, M. Rigas, A. Syntos, and C. Stefanidis, “Beneficial effects of statins on endothelial dysfunction and vascular stiffness,” Current Vascular Pharmacology, vol. 5, no. 3, pp. 227–237, 2007.

[106] U. Laufs, M. Endres, F. Custodis et al., “Suppression of endothelial nitric oxide production after withdrawal of statin treatment is mediated by negative feedback regulation of rho GTPase gene transcription,” Circulation, vol. 102, no. 25, pp. 3104–3110, 2000.

[107] U. Laufs and J. K. Liao, “Post-transcriptional regulation of endothelial nitric oxide synthase mRNA stability by Rho GTPase*,” The Journal of Biological Chemistry, vol. 273, no. 37, pp. 24266–24271, 1998.

[108] B. Tesfamariam, “The effects of HMG-CoA reductase inhibitors on endothelial function,” American Journal of Cardiovascular Drugs, vol. 6, no. 2, pp. 115–120, 2006.

[109] S. Dimmeler, I. Fleming, B. Fisslthaler, C. Hermann, R. Busse, and A. M. Zeiher, “Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation,” Nature, vol. 399, no. 6736, pp. 601–605, 1999.

[110] D. Fulton, J.-P. Gratton, T. J. McCabe et al., “Regulation of endothelium-derived nitric oxide production by the protein kinase Akt,” Nature, vol. 399, no. 6736, pp. 597–601, 1999.

[111] S. Wolfrum, A. Dendorfer, Y. Rikitake et al., “Inhibition of Rho-kinase leads to rapid activation of phosphatidylinositol 3-kinase/protein kinase Akt and cardiovascular protection,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 24, no. 10, pp. 1842–1847, 2004.

[112] O. Hernández-Perera, D. Pérez-Sala, J. Navarro-Antolín et al., “Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells,” The Journal of Clinical Investigation., vol. 101, no. 12, pp. 2711–2719, 1998.

[113] T. Hisada, M. Ayaori, N. Ohrui et al., “Statin inhibits hypoxia-induced endothelin-1 via accelerated degradation of HIF-1α in vascular smooth muscle cells,” Cardiovascular Research, vol. 95, no. 2, pp. 251–259, 2012.

[114] J. K. Liao and U. Laufs, “Pleiotropic effects of statins,” Annual Review of Pharmacology and Toxicology, vol. 45, no. 1, pp. 89–118, 2005.

[115] T. Ichihi, K. Takeda, T. Tokunou et al., “Downregulation of angiotensin II type 1 receptor by hydrobolic 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in vascular
smooth muscle cells,” *Arteriosclerosis, Thrombosis, and Vascular Biology*, vol. 21, no. 12, pp. 1896–1901, 2001.

[116] G. Nickenig, A. T. Bäumer, Y. Temur, D. Kebben, F. Jockenhövel, and M. Böhm, “Statin-sensitive dysregulated AT1 receptor function and density in hypercholesterolemic men,” *Circulation*, vol. 100, no. 21, pp. 2131–2134, 1999.

[117] A. Sahebkar, K. Kotani, C. Serban et al., “Statin therapy reduces plasma endothelin-1 concentrations: a meta-analysis of 15 randomized controlled trials,” *Atherosclerosis*, vol. 241, no. 2, pp. 433–442, 2015.

[118] S. Wassmann, U. Laufs, A. T. Bäumer et al., “HMG-CoA reductase inhibitors improve endothelial dysfunction in normocholesterolemic hypertension via reduced production of reactive oxygen species,” *Hypertension*, vol. 37, no. 6, pp. 1450–1457, 2001.

[119] A. M. Briones, N. Rodriguez-Criado, R. Hernanz et al., “Atorvastatin prevents angiotensin II-induced vascular remodeling and oxidative stress,” *Hypertension*, vol. 54, no. 1, pp. 142–149, 2009.

[120] P. L. Hordijk, “Regulation of NADPH oxidases: the role of Rac proteins,” *Circulation Research*, vol. 98, no. 4, pp. 453–462, 2006.

[121] P. Y. Lin, F. Y. Lee, C. G. Wallace et al., “The therapeutic effect of rosuvastatin and propylthiouracil on ameliorating high-cholesterol diet-induced rabbit aortic atherosclerosis and stiffness,” *International Journal of Cardiology*, vol. 227, pp. 938–949, 2017.

[122] C. Petit, F. Batool, I. M. Bugueno, P. Schwinté, N. Benkirane-Jessel, and O. Huck, “Contribution of statins towards periodontal treatment: a review,” *Mediators of Inflammation*, vol. 2019, 33 pages, 2019.

[123] E. M. Aguilar, J. D. H. Miralles, A. F. González, C. V. Casariego, S. B. Moreno, and F. A. García, “In vivo confirmation of the role of statins in reducing nitric oxide and C-reactive protein levels in peripheral arterial disease,” *European Journal of Vascular and Endovascular Surgery*, vol. 37, no. 4, pp. 443–447, 2009.

[124] O. Feron, C. Dessy, J.-P. Desager, and J.-L. Balligand, “Hydroxy-methylglutaryl–coenzyme A reductase inhibition promotes endothelial nitric oxide synthase activation through a decrease in caveolin abundance,” *Circulation*, vol. 103, no. 1, pp. 113–118, 2001.

[125] O. Feron, C. Dessy, S. Moniotte, J.-P. Desager, and J.-L. Balligand, “Hypercholesterolemia decreases nitric oxide production by promoting the interaction of caveolin and endothelial nitric oxide synthase,” *The Journal of clinical investigation.*, vol. 103, no. 6, pp. 897–905, 1999.

[126] G. A. Plenz, O. Hofnagel, and H. Robenek, “Differential modulation of caveolin-1 expression in cells of the vasculature by,” *Circulation*, vol. 109, pp. e7–e8, 2004.

[127] S. Dunzendorfer, D. Rothbacher, P. Schratzberger, N. Reinsch, C. M. Kähler, and C. J. Wiedermann, “Mevalonate-dependent inhibition of transendothelial migration and chemotaxis of human peripheral blood neutrophils by pravastatin,” *Circulation Research*, vol. 81, no. 6, pp. 963–969, 1997.

[128] H. Kothe, K. Dalhoff, J. Rupp et al., “Hydroxymethylglutaryl coenzyme A reductase inhibitors modify the inflammatory response of human macrophages and endothelial cells infected with Chlamydia pneumoniae,” *Circulation*, vol. 101, no. 15, pp. 1760–1763, 2000.

[129] F. Tissier, Y. Mallem, C. Goanvec et al., “A non-hypcholesterolemic atorvastatin treatment improves vessel elasticity by acting on elastin composition in WHHL rabbits,” *Atherosclerosis*, vol. 251, pp. 70–77, 2016.

[130] A. C. Calkin, S. Giunti, K. J. Sheehy et al., “The HMG-CoA reductase inhibitor rosuvastatin and the angiotensin receptor antagonist candesartan attenuate atherosclerosis in an apolipoprotein E-deficient mouse model of diabetes via effects on advanced glycation, oxidative stress and inflammation,” *Diabetologia*, vol. 51, no. 9, pp. 1731–1740, 2008.

[131] A. K. Sinha and J. L. Mehta, “Modulation of atherosclerosis, blood pressure and arterial elasticity by statins,” *Advances in Cardiology*, vol. 44, pp. 315–330, 2007.

[132] I. Koniaris, D. Mavrilas, E. Apostolakis et al., “Inhibition of atherosclerosis progression, intimal hyperplasia, and oxidative stress by simvastatin and ivabradine may reduce thoracic aorta’s stiffness in hypercholesterolemic rabbits,” *Journal of Cardiovascular Pharmacology and Therapeutics*, vol. 21, no. 4, pp. 412–422, 2016.

[133] R. P. Wildman, R. H. Mackey, A. Bostom, T. Thompson, and K. Sutton-Tyrrell, “Measures of obesity are associated with vascular stiffness in young and older adults,” *Hypertension*, vol. 42, no. 4, pp. 468–473, 2003.

[134] C. Vlachopoulos, K. Aznauoridis, D. Terentes-Printzios, N. Ioakeimidis, and C. Stefanidis, “Prediction of cardiovascular events and all-cause mortality with brachial-ankle elasticity index: a systematic review and meta-analysis,” *Hypertension*, vol. 60, no. 2, pp. 556–562, 2012.